Mergers & Acquisitions ·
On September 27, 2026, Lifecore Biomedical entered into a definitive merger agreement with an affiliate of Webster…
LFCRLifecore Biomedical, Inc. de
On September 27, 2026, Lifecore Biomedical entered into a definitive merger agreement with an affiliate of Webster Equity Partners. Under the terms, common stockholders will receive $6.28 per share in cash plus one contingent value right (CVR) per share. The transaction is valued at up to approximately $663.7 million, assuming full achievement of performance milestones totaling $160 million across 2028–2030. Webster has secured $400 million in equity financing and $180 million in debt commitments to fund the acquisition. The deal requires stockholder approval and regulatory clearance under the Hart-Scott-Rodino Act, with a closing expected by the end of Q4 2026. Lifecore operates as a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products.